Story
Annexon Shares Fall After Key Clinical Trial Protocol Change

Shares of Annexon (NASDAQ: ANNX) fell in pre-market trading after the company disclosed a significant amendment to its pivotal late-stage trial for a key drug candidate, prompting investor concern ahead of topline data.
Trial Protocol Amended
Annexon announced it has modified the design of its Phase 3 ARCHER II trial, which is evaluating vonaprument as a treatment for dry age-related macular degeneration with geographic atrophy. The company has added a month 24 co-primary endpoint to the study, supplementing the original primary endpoint at month 15.
Key details of the trial and amendment include:
- The study, which completed enrollment of 659 patients in July 2025, can now meet its primary objective at either the 15-month or 24-month mark.
- The primary endpoint measures the proportion of patients who experience a significant loss of vision, defined as a loss of 15 or more letters in best corrected visual acuity at two consecutive visits.
Market Reaction and Investor Concerns
AdThe stock dropped 6.4% in pre-open trading on the news. Mid-study changes to a clinical trial's primary endpoints are often viewed negatively by investors, as they can be interpreted as a sign of wavering confidence in the ability to meet the original, earlier goal.
This concern is heightened by the proximity of the trial's topline data readout, which is expected in Q4 2026. This data release represents a pivotal binary event for the company. The stock's decline occurred despite modest gains in the broader S&P 500 and Nasdaq indices, indicating the pressure is company-specific.
Company-Specific Headwinds
Adding to near-term caution is Annexon's upcoming earnings report, scheduled for August 17, 2026, which may be prompting some investors to reduce their exposure. As a clinical-stage company with no product revenue, Annexon relies on equity financing to fund its pipeline.
This financial structure makes its stock particularly sensitive to any news that could alter the perceived risk profile of its lead drug programs. The combination of the trial amendment and the approaching earnings report has created significant downward pressure on the shares.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.